← FDA DRUG APPROVALS

FDA ANDA · ANDA065037

IDARUBICIN HYDROCHLORIDE

Sponsor: TEVA PARENTERAL

APPLICATION
ANDA065037
TYPE
ANDA
ORIGINAL APPROVAL
2002-05-01
LATEST ACTION
2002-05-01
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Discontinued

Products

IDARUBICIN HYDROCHLORIDEDiscontinued
IDARUBICIN HYDROCHLORIDE 5MG/VIAL · POWDER · INTRAVENOUS
IDARUBICIN HYDROCHLORIDEDiscontinued
IDARUBICIN HYDROCHLORIDE 20MG/VIAL · POWDER · INTRAVENOUS
IDARUBICIN HYDROCHLORIDEDiscontinued
IDARUBICIN HYDROCHLORIDE 10MG/VIAL · POWDER · INTRAVENOUS

Approval history

2002-05-01Original — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →